NTCIR-17 Medical Natural Language Processing for Social media and Clinical texts (MedNLP-SC)

Eiji ARAMAKI, Ph.D. @ NAIST Yuta NAKAMURA, Ph.D., M.D. @ The University of Tokyo

Organizers



Co-chair (general)

Eiji Aramaki, Ph.D. (NAIST, Japan)



Co-chair (general)

Shoko Wakamiya, Ph.D. (NAIST, Japan)



Co-chair (SM Subtask)

Co-chair (RR Subtask) Shuntaro Yada, Ph.D. (NAIST, Japan) Yuta Nakamura, M.D. (The University of Tokyo, Japan)

SM Subtask

Saclay, CNRS, LISN, France)

SM Subtask Aurélie Névéol, Ph.D. (Université

Paris-Saclay, CNRS, LISN, France)



SM Subtask

SM Subtask

Patrick Paroubek, Ph.D. (Université Hui-Syuan Yeh (Université Paris-Paris-Saclay, CNRS, LISN, France) Saclay, CNRS, LISN, France)



SM Subtask

Pierre Zweigenbaum, Ph.D. (Université Paris-Saclay, CNRS, LISN, France)



Gabriel Herman Bernardim Andrade

SM Subtask

(NAIST, Japan)



SM Subtask

SM Subtask

Lisa Raithel (DFKI, Germany, TU Faith Wavinya Mutinda, Ph.D. (NAIST, Tomohiro Nishiyama (NAIST, Japan) Berlin, Germany, and Université Paris-Japan)



SM Subtask



Philippe Thomas, Ph.D. (DFKI, Germany)

SM Subtask



SM Subtask

Saclay, CNRS, LISN, France)

SM Subtask



Paris-Saclay, CNRS, LISN, France)



Akiko Aizawa, Ph.D. (NII, Japan)

Japan)

SM Subtask

Hiroki Teranishi, Ph.D. (RIKEN,



SM Subtask

Narumi Tokunaga (RIKEN, Japan)



Peitao Han (NAIST, Japan)

Lis Weiji Kanashiro Pereira Ph.D. (NAIST, Japan)

DFG JST anr°



RR Subtask

Shouhei Hanaoka, M.D., Ph.D. (The University of Tokyo, Japan)



SM Subtask Yuji Matsumoto, Ph.D. (RIKEN,

Noriki Nishida, Ph.D. (RIKEN, Japan)

















MedNLP-SC Subtasks

- Social Media Adverse Drug Event detection (SM-ADE)
 - Identify a set of symptoms caused by a drug from short messages written by social media users
 - Social media corpus in Japanese, English, German, and French
 - Radiology Report TNM staging (RR-TNM)
 - Determine the clinical stage of lung cancer from radiology reports, which requires clinical knowledge and complex reasoning
 - Radiology report corpus in Japanese



Co-chair (general)

Eiji Aramaki, Ph.D. (NAIST, Japan)



Co-chair (RR Subtask)

Yuta Nakamura, M.D. (The University of Tokyo, Japan)

RR-TNM Subtask

<u>**RR</u>-TNM subtask**</u>

→ <u>R</u>adiology <u>R</u>eport

Clinical documents from radiologists to physicians





(These illustrations were created by GPT-4V)

RR-<u>TNM</u> subtask

TNM staging of lung cancer

Precise evaluation of cancer progression (staging) is essential



Motivation

- Staging is complex
 - Three-label classification
 - Complicated criteria



T0: No primary tumor

Tis: Ground-glass nodule without solid component with the total diameter \leq 3 cm T1mi: Ground-glass nodule with solid component \leq 0.5 cm and the total diameter \leq 3 cm

T1a: Solid component diameter ≤1 cm

T1b: Solid component diameter >1 cm and \leq 2 cm

T1c: Solid component diameter >2 cm and \leq 3 cm

T2a: Solid component diameter >3 cm and ≤4 cm. Otherwise, extension to main bronchus or visceral pleura, or atelectasis or obstructive pneumonia extending to hilum," with the solid component diameter <3 cm or unknown

T2b: Solid component diameter >4 cm and \leq 5 cm

T3: Solid component diameter >5 cm and \leq 7 cm. Otherwise, solid component diameter \leq 5 cm and either condition holds: direct invasion of parietal pleura, chest wall (including superior sulcus tumor), mediastinal nerve, or pericardium; separate tumor nodule(s) in the same lobe

T4: Solid component diameter >7 cm. Otherwise, either condition holds: invasion of diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, spine, or carina; tumor nodule(s) in a different ipsilateral lobe

N0: No regional lymph node metastasis

N1: Metastasis to ipsilateral peribronchial, hilar, or pulmonary lymph nodes, including direct invasion of the primary tumor

N2: Metastasis to ipsilateral mediastinal or subcarinal lymph nodes

N3: Metastasis to contralateral mediastinal, hilar, anterior scalene, or supraclavicular lymph nodes

M0: No distant metastasis

M1a: Contralateral tumor nodule(s), pleural or pericardial nodule(s), malignant pleural effusion, or malignant pericardial effusion M1b: Single extrathoracic metastasis M1c: Multiple extrathoracic metastases

Motivation

T0: No primary tumor

cm

• Staging is complex

Tis: Ground-glass nodule without solid

T1mi: Ground-glass nodule with solid

T1a: Solid component diameter ≤1 cr T1b: Solid component diameter >1 cr

T1c: Solid component diameter >2 cr

T2a: Solid component diameter >3 cr bronchus or visceral pleura, or atelect

hilum," with the solid component dia T2b: Solid component diameter >4 cr

T3: Solid component diameter >5 cm

diameter ≤ 5 cm and either condition

wall (including superior sulcus tumor), tumor nodule(s) in the same lobe

T4: Solid component diameter >7 cm

diaphragm, mediastinum, heart, great

esophagus, spine, or carina; tumor no

• Three-label classification

Complicated criteria



• TNM stage is not often explicitly mentioned in radiology reports (Sexauer et al., 2018)



- Patient care or secondary usage of information can be hampered
- We aim to evaluate the capability of NLP systems to automatically assign TNM stage based on radiology reports

Task scheme

• Three-label document classification



Dataset

- 243 Japanese radiology reports
- Contains no personal information
- 9 radiologists diagnosed 27 cases
- Case-level split (training : validation : test = 12:6:9 cases)
- Gold standards were assigned by the radiologists writing the radiology reports



Evaluation metrics

Separate evaluation: T/N/M accuracy

Accuracy scores calculated independently for T, N, and M categories



Joint accuracy

Fraction of cases whose T, N, and M categories were all predicted correctly



Potential challenge

• Complicated criteria requiring detailed domain-specific knowledge

T0: No primary tumor

Tis: Ground-glass nodule without solid component with the total diameter \leq 3 cm T1mi: Ground-glass nodule with solid component \leq 0.5 cm and the total diameter \leq 3 cm

T1a: Solid component diameter \leq 1 cm

T1b: Solid component diameter >1 cm and \leq 2 cm

T1c: Solid component diameter >2 cm and \leq 3 cm

T2a: Solid component diameter >3 cm and \leq 4 cm. Otherwise, extension to main bronchus or visceral pleura, or atelectasis or obstructive pneumonia extending to hilum," with the solid component diameter <3 cm or unknown

T2b: Solid component diameter >4 cm and \leq 5 cm

T3: Solid component diameter >5 cm and \leq 7 cm. Otherwise, solid component diameter \leq 5 cm and either condition holds: direct invasion of parietal pleura, chest wall (including superior sulcus tumor), mediastinal nerve, or pericardium; separate tumor nodule(s) in the same lobe

T4: Solid component diameter >7 cm. Otherwise, either condition holds: invasion of diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, spine, or carina; tumor nodule(s) in a different ipsilateral lobe

N0: No regional lymph node metastasis

N1: Metastasis to ipsilateral peribronchial, hilar, or pulmonary lymph nodes, including direct invasion of the primary tumor

N2: Metastasis to ipsilateral mediastinal or subcarinal lymph nodes

N3: Metastasis to contralateral mediastinal, hilar, anterior scalene, or supraclavicular lymph nodes

M0: No distant metastasis

M1a: Contralateral tumor nodule(s), pleural or pericardial nodule(s), malignant pleural effusion, or malignant pericardial effusion M1b: Single extrathoracic metastasis M1c: Multiple extrathoracic metastases

Participant solutions

- 7 solutions from 3 teams (including baseline)
- KRad team (Nishio et al.)
 - LLM <u>gpt-3.5-turbo</u> + in-context learning
- kuhp team (Fujimoto et al.)
 - LLM <u>openCALM-7B</u> + instruction tuning
- NAISTSOCRR team (Fukushima et al.)
 - smaller model <u>BERT/RoBERTa</u> + fine-tuning
 - Majority baseline (always answer T1N0M0)

Participant solutions

- 7 solutions from 3 teams (including baseline)
- KRad team (Nishio et al.)
 - LLM <u>gpt-3.5-turbo</u> + in-context learning
- kuhp team (Fujimoto et al.)
 - LLM <u>openCALM-7B</u> + instruction tuning
- NAISTSOCRR team (Fukushima et al.)
 - smaller model <u>BERT/RoBERTa</u> + fine-tuning
 - Majority baseline (always answer T1N0M0)

Presenting criteria in the prompt

Custom QA dataset for instruction tuning + data augmentation

Pre-trained models in biomedical domain

Results

All solutions outperformed baseline



Results

All solutions outperformed baseline

Tendency: T < N ∢ M





Why T<N<M?

Class: T(5) > N(4) > M(2)

Complexity of criteria: T >> N, M



T: primary <u>t</u>umor

- Tumor size in mm?
- Invading to where?
- How many satellite lesions?

N: metastasis to lymph <u>n</u>odes

• To what lymph nodes?

M: metastasis to distant organsNo/Single/multiple?

T criteria is complex

T: primary <u>t</u>umor

- Tumor size in mm?
- Invading to where?
- How many satellite lesions?

T0: No primary tumor

Tis: Ground-glass nodule without solid component with the total diameter \leq 3 cm

T1mi: Ground-glass nodule with solid component \leq 0.5 cm and the total diameter \leq 3 cm

T1a: Solid component diameter ≤1 cm

T1b: Solid component diameter >1 cm and \leq 2 cm

T1c: Solid component diameter >2 cm and \leq 3 cm

T2a: Solid component diameter >3 cm and ≤4 cm. Otherwise, extension to main bronchus or visceral pleura, or atelectasis or

obstructive pneumonia extending to hilum," with the solid component diameter <3 cm or unknown

T2b: Solid component diameter >4 cm and \leq 5 cm

T3: Solid component diameter >5 cm and \leq 7 cm. Otherwise, solid component diameter \leq 5 cm and either condition holds: direct invasion of parietal pleura, chest wall (including superior sulcus tumor), mediastinal nerve, or pericardium; separate tumor nodule(s) in the same lobe

T4: Solid component diameter >7 cm. Otherwise, either condition holds: invasion of diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, spine, or carina; tumor nodule(s) in a different ipsilateral lobe

T criteria is complex

T: primary <u>t</u>umor

- Tumor size in mm?
- Invading to where?
- How many satellite lesions?

T0: No primary tumor

Tis: Ground-glass nodule without solid component with the total diameter \leq 3 cm

T1mi: Ground-glass nodule with solid component \leq 0.5 cm and the total diameter \leq 3 cm

T1a: Solid component diameter ≤1 cm

T1b: Solid component diameter >1 cm and \leq 2 cm

T1c: Solid component diameter >2 cm and \leq 3 cm

Solid component diameter

Ground-glass nodule

Total diameter

Mark M. Hammer et al., 2020

T2a: Solid component diameter >3 cm and \leq 4 cm. Otherwise, extension to main bronchus or visceral pleura, or atelectasis or

<mark>obstructive pneumonia extending to hilum,"</mark> with the solid component diameter <3 cm or unknown

T2b: Solid component diameter >4 cm and \leq 5 cm

T3: Solid component diameter >5 cm and ≤7 cm. Otherwise, solid component diameter ≤5 cm and either condition holds: direct invasion of parietal pleura, chest wall (including superior sulcus tumor), mediastinal nerve, or pericardium; separate tumor nodule(s) in the same lobe

T4: Solid component diameter >7 cm. Otherwise, either condition holds: invasion of diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, spine, or carina; tumor nodule(s) in a different ipsilateral lobe

T criteria is complex

T: primary <u>t</u>umor

- Tumor size in mm?
- Invading to where?
- How many satellite lesions?

Requires anatomical understanding

Invading ribs ⊂ Invading chest wall

T0: No primary tumor

Tis: Ground-glass nodule without solid component with the total diameter \leq 3 cm

T1mi: Ground-glass nodule with solid component \leq 0.5 cm and the total diameter \leq 3 cm

T1a: Solid component diameter ≤1 cm

T1b: Solid component diameter >1 cm and \leq 2 cm

T1c: Solid component diameter >2 cm and \leq 3 cm

T2a: Solid component diameter >3 cm and \leq 4 cm. Otherwise, extension to main bronchus or visceral pleura, or atelectasis or

<mark>obstructive pneumonia extending to hilum,"</mark> with the solid component diameter <3 cm or unknown

T2b: Solid component diameter >4 cm and \leq 5 cm

T3: Solid component diameter >5 cm and <7 cm. Otherwise, solid component diameter ≤5 cm and either condition holds: direct

invasion of parietal pleura<mark>, chest wall (including superior sulcus tumor),</mark> mediastinal nerve, or pericardium; separate tumor nodule(s) in the same lobe

T4: Solid component diameter >7 cm. <mark>Otherwise, either condition holds: invasion of diaphragm, mediastinum, heart, great vessels,</mark> <mark>trachea, recurrent laryngeal nerve, esophagus, spine, or carina;</mark> tumor nodule(s) in a different ipsilateral lobe

T criteria is complex

Recall scores tended to

- Higher in early (T1–T2) or very progressed (T4) cancers
- Lower in T3 cancers

| | KRad_1 | NAISTSOCRR_1 | NAISTSOCRR_2 | <pre>baseline_3</pre> | kuhp_1 | kuhp_2 | kuhp_3 |
|-----------|----------|--------------|--------------|-----------------------|----------|----------|----------|
| то | 0.500000 | 0.000000 | 0.000000 | 0.0 | 0.000000 | 0.000000 | 0.000000 |
| T1 | 0.040000 | 0.720000 | 1.000000 | 1.0 | 0.400000 | 0.520000 | 0.520000 |
| T2 | 0.666667 | 0.000000 | 0.333333 | 0.0 | 0.333333 | 0.500000 | 0.500000 |
| Т3 | 0.400000 | 0.000000 | 0.000000 | 0.0 | 0.200000 | 0.200000 | 0.200000 |
| Т4 | 0.560976 | 0.756098 | 0.658537 | 0.0 | 0.634146 | 0.487805 | 0.463415 |
| | LLM | BERT | BERT | | LLM | LLM | LLM |

Indeterminate mentions

Presence/absence of image findings are often difficult to determine due to indeterminate mentions in radiology reports

😢 A test sample failed by all teams for N category prediction

- 「右肺門リンパ節がやや腫大しており、転移を否定できません。」
- Moderate right hilar lymphadenopathy is noted: <u>metastasis cannot be</u> <u>ruled out</u>.
 - V1 (lymph node metastasis is present)
 - X N0 (lymph node metastasis is absent)

Future direction

• Further exploration for better performance is valuable for real-world applications

Remaining issues

- This subtask was limited to Japanese data
- How to create open radiology report datasets to non-Japanese languages?



Acknowledgement

We greatly appreciate Y's Reading, Inc., a teleradiology company in Kumamoto, Japan, for continuous support in creating an open Japanese radiology report corpus

